大剂量糖皮质激素静脉冲击治疗甲状腺相关眼病的研究被引量：8

Study Progress of High Dose Intravenous Glucocorticoid Pulse Therapy in the Treatment of Thyroid-associated Ophthalmopathy

下载PDF

导出

摘要甲状腺相关性眼病(TAO)是一种器官特异性自身免疫性疾病,临床表现为多种眼征,目前对本病的治疗尚不满意。近10余年来,对糖皮质激素治疗TAO的机制有了进一步的认识,而大剂量糖皮质激素静脉冲击方案在治疗TAO方面显示了较大的优越性,除眼球突出以及由此导致的复视效果并不肯定外,其对眼部软组织炎症、视神经病变、眼外肌功能障碍者效果优良,对于病程较短、病情较重的活动期患者尤然;而且,这种疗法副作用少,患者依从性较佳,值得临床上进一步推广与探索。 Thyreid-associated ophthalmopathy（TAO）is an organ-specific autoimmune process with a variety of clinical ocular symptoms and signs. There is still not satisfactory treatment for this disease at present. In recent 10 years, with further acknowledgement in the mechanism of glucocorticoid in treating TAO, high dose intravenous glucoeorticoid pulse therapy has showed its huge advantages in treating this disease, especially including soft tissue inflammation in ocular region,optic neuropathy,oculorotatory muscles dysfunction although its effect in ophthalmoptosis and diplopia resulting from it is not affirmative yet. Patients in active stage with short course and severe pathogenetic condition will benefit from the method most. This treatment with few side effects and fine compliance of patients is worth further applying and research.

作者蒋琳王爱萍刘超

机构地区南京医科大学第一附属医院内分泌科中国人民解放军第

出处《医学综述》 2006年第24期1528-1531,共4页 Medical Recapitulate

关键词格雷夫斯病糖皮质激素甲泼尼龙静脉冲击治疗 Graves＇ disease Glucocorticoid Methylprednisolone Intravenous pulse therapy

分类号 R581.1 [医药卫生—内分泌] R459.1 [医药卫生—治疗学]

引文网络
相关文献

参考文献19

1Marcccci C,Mareino M,Rocchi R,et al.Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy:the first European Group on Graves' Orbitopathy experience[ J].Eur J Endocrinol,2003,148(5):491-495.
2Bartalena L,Pinchera A,Marcocci C.Management of Graves' ophthalmopathy:reality and perspectives[ J ].Endocr Rev,2000,21 (2):168-199.
3Bartalena L,Marcocci C,Tanda ML,et al.An update on medical management of Graves' ophthalmopathy[ J ].J Endocrinol Invest,2005,28(5):469-478.
4Marcocci C,Bartalena L,Tanda ML,et al.Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy:results of a prospective,single-blind,randomized study[ J ].JClin Endocrinol Metab,2001,86(8):3562-3567.
5Kauppinen-Makelin R,Karma A,Leinonen E,et al.High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-aasociated ophthalmopathy[ J].Acta Ophthalmol Scand,2002,80(3):316-321.
6Ebner R,Devoto MH,Weil D,et al.Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone[ J ].Br J Ophthalmol,2004,88(11):1380-1386.
7Goldberg RA.Orbital steroid injections[J].Br J Ophthalmo1,2004,88(11):1359-1360.
8Perros P,Kendall-Taylor P.Medical treatment for thyroid-aasociated ophthalmopathy[J].Thyroid,2002,12(3):241-244.
9Kendall-Taylor P,Crombie AL,Stephenson AM,et al.Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy[ J].Br Med J,1988,297(6663):1574-1578.
10Nagayama Y,Izumi M,Kiriyama T,et al.Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy[J].Acta Endocrinol,1987,116(4):513-518.